Prostaglandin E1 therapy of newborns with group B beta-hemolytic streptococci-induced pulmonary hypertension

T. Machay, A. Nobilis, J. Hajdú, Z. S. Somogyvari, Z. Papp

Research output: Contribution to journalArticle

Abstract

Four newborns with group B beta-hemolytic streptococci (GBS)-induced pulmonary hypertension and hypoxemia were treated with hyperventilation and Tolazoline without significant improvement in oxygenation. The patients were divided into two randomized groups thereafter: one to receive an infusion of Prostaglandin E1 (PGE1) and the others to receive Tolazoline (controls). Patients treated with PGE1 (n = 2) showed significant improvement in oxygenation. The arterial-alveolar oxygen ratio (a/A) increased from 0.047 (± 0.003) to 0.091 (± 0.03) (p <0.001); the oxygenation index (OI), incorporating mean airway pressure (MAP) as well as oxygen variables improved significantly from 56.6 (± 0.55) to 36.4 (± 15.6) (p <0.001) 30 minutes after the start of the PGE1 infusion. This improvement was maintained in these patients for the whole time of PGE1 infusion and thereafter. The controls (n = 2) did not show improvement in oxygenation. Only the two newborns that received PGE1 therapy survived out of the four. No systemic hypotension was observed during the PGE''1 infusion. These findings suggest that PGE1 infusion may provide therapeutic benefits for newborns with persistent pulmonary hypertension (PPHN) once hyperventilation and Tolazoline treatment were ineffective.

Original languageEnglish
Pages (from-to)187-201
Number of pages15
JournalActa Paediatrica Hungarica
Volume33
Issue number3-4
Publication statusPublished - 1993

Fingerprint

Alprostadil
Streptococcus
Pulmonary Hypertension
Tolazoline
Newborn Infant
Hyperventilation
Therapeutics
Persistent Fetal Circulation Syndrome
Oxygen
Prostaglandins E
Hypotension
Pressure

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Prostaglandin E1 therapy of newborns with group B beta-hemolytic streptococci-induced pulmonary hypertension. / Machay, T.; Nobilis, A.; Hajdú, J.; Somogyvari, Z. S.; Papp, Z.

In: Acta Paediatrica Hungarica, Vol. 33, No. 3-4, 1993, p. 187-201.

Research output: Contribution to journalArticle

@article{11bf66ff33a6438cb7324a1020e35ca4,
title = "Prostaglandin E1 therapy of newborns with group B beta-hemolytic streptococci-induced pulmonary hypertension",
abstract = "Four newborns with group B beta-hemolytic streptococci (GBS)-induced pulmonary hypertension and hypoxemia were treated with hyperventilation and Tolazoline without significant improvement in oxygenation. The patients were divided into two randomized groups thereafter: one to receive an infusion of Prostaglandin E1 (PGE1) and the others to receive Tolazoline (controls). Patients treated with PGE1 (n = 2) showed significant improvement in oxygenation. The arterial-alveolar oxygen ratio (a/A) increased from 0.047 (± 0.003) to 0.091 (± 0.03) (p <0.001); the oxygenation index (OI), incorporating mean airway pressure (MAP) as well as oxygen variables improved significantly from 56.6 (± 0.55) to 36.4 (± 15.6) (p <0.001) 30 minutes after the start of the PGE1 infusion. This improvement was maintained in these patients for the whole time of PGE1 infusion and thereafter. The controls (n = 2) did not show improvement in oxygenation. Only the two newborns that received PGE1 therapy survived out of the four. No systemic hypotension was observed during the PGE''1 infusion. These findings suggest that PGE1 infusion may provide therapeutic benefits for newborns with persistent pulmonary hypertension (PPHN) once hyperventilation and Tolazoline treatment were ineffective.",
author = "T. Machay and A. Nobilis and J. Hajd{\'u} and Somogyvari, {Z. S.} and Z. Papp",
year = "1993",
language = "English",
volume = "33",
pages = "187--201",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Verlag",
number = "3-4",

}

TY - JOUR

T1 - Prostaglandin E1 therapy of newborns with group B beta-hemolytic streptococci-induced pulmonary hypertension

AU - Machay, T.

AU - Nobilis, A.

AU - Hajdú, J.

AU - Somogyvari, Z. S.

AU - Papp, Z.

PY - 1993

Y1 - 1993

N2 - Four newborns with group B beta-hemolytic streptococci (GBS)-induced pulmonary hypertension and hypoxemia were treated with hyperventilation and Tolazoline without significant improvement in oxygenation. The patients were divided into two randomized groups thereafter: one to receive an infusion of Prostaglandin E1 (PGE1) and the others to receive Tolazoline (controls). Patients treated with PGE1 (n = 2) showed significant improvement in oxygenation. The arterial-alveolar oxygen ratio (a/A) increased from 0.047 (± 0.003) to 0.091 (± 0.03) (p <0.001); the oxygenation index (OI), incorporating mean airway pressure (MAP) as well as oxygen variables improved significantly from 56.6 (± 0.55) to 36.4 (± 15.6) (p <0.001) 30 minutes after the start of the PGE1 infusion. This improvement was maintained in these patients for the whole time of PGE1 infusion and thereafter. The controls (n = 2) did not show improvement in oxygenation. Only the two newborns that received PGE1 therapy survived out of the four. No systemic hypotension was observed during the PGE''1 infusion. These findings suggest that PGE1 infusion may provide therapeutic benefits for newborns with persistent pulmonary hypertension (PPHN) once hyperventilation and Tolazoline treatment were ineffective.

AB - Four newborns with group B beta-hemolytic streptococci (GBS)-induced pulmonary hypertension and hypoxemia were treated with hyperventilation and Tolazoline without significant improvement in oxygenation. The patients were divided into two randomized groups thereafter: one to receive an infusion of Prostaglandin E1 (PGE1) and the others to receive Tolazoline (controls). Patients treated with PGE1 (n = 2) showed significant improvement in oxygenation. The arterial-alveolar oxygen ratio (a/A) increased from 0.047 (± 0.003) to 0.091 (± 0.03) (p <0.001); the oxygenation index (OI), incorporating mean airway pressure (MAP) as well as oxygen variables improved significantly from 56.6 (± 0.55) to 36.4 (± 15.6) (p <0.001) 30 minutes after the start of the PGE1 infusion. This improvement was maintained in these patients for the whole time of PGE1 infusion and thereafter. The controls (n = 2) did not show improvement in oxygenation. Only the two newborns that received PGE1 therapy survived out of the four. No systemic hypotension was observed during the PGE''1 infusion. These findings suggest that PGE1 infusion may provide therapeutic benefits for newborns with persistent pulmonary hypertension (PPHN) once hyperventilation and Tolazoline treatment were ineffective.

UR - http://www.scopus.com/inward/record.url?scp=0027819343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027819343&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 187

EP - 201

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 3-4

ER -